1. Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
- Author
-
Nakamura, Kazufumi, Akagi, Satoshi, Ejiri, Kentaro, Taya, Satoshi, Saito, Yukihiro, Kuroda, Kazuhiro, Takaya, Yoichi, Toh, Norihisa, Nakayama, Rie, Katanosaka, Yuki, and Yuasa, Shinsuke
- Subjects
VASCULAR remodeling ,PULMONARY hypertension ,TRP channels ,HYPOXIA-inducible factors ,LUNG diseases ,VASOCONSTRICTION ,LUNGS - Abstract
Pulmonary hypertension associated with lung diseases and/or hypoxia is classified as group 3 in the clinical classification of pulmonary hypertension. The efficacy of existing selective pulmonary vasodilators for group 3 pulmonary hypertension is still unknown, and it is currently associated with a poor prognosis. The mechanisms by which pulmonary hypertension occurs include hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, a decrease in pulmonary vascular beds, endothelial dysfunction, endothelial-to-mesenchymal transition, mitochondrial dysfunction, oxidative stress, hypoxia-inducible factors (HIFs), inflammation, microRNA, and genetic predisposition. Among these, hypoxic pulmonary vasoconstriction and subsequent pulmonary vascular remodeling are characteristic factors involving the pulmonary vasculature and are the focus of this review. Several factors have been reported to mediate vascular remodeling induced by hypoxic pulmonary vasoconstriction, such as HIF-1α and mechanosensors, including TRP channels. New therapies that target novel molecules, such as mechanoreceptors, to inhibit vascular remodeling are awaited. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF